secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001213900-25-015851
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose
--------------------------------------------------------------------------------

- First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.
- DSMB approved escalation to second cohort at 5 million receptor-positive T cells/kg of EB103 therapy.
- Preliminary data showed tumor responses in all patients at Month 1; favorable safety profile.
- STARLIGHT-1 is an open-label, multi-center 3+3 dose-escalation study to determine RP2D for EB103.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025015851/0001213900-25-015851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025015851/ea023173701-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-015851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer